Limits...
Tegaserod in the treatment of irritable bowel syndrome (IBS) with constipation as the prime symptom.

Layer P, Keller J, Loeffler H, Kreiss A - Ther Clin Risk Manag (2007)

Bottom Line: Moreover, tegaserod was associated with improvements in patients' quality of life and work productivity.Diarrhea is the only adverse event consistently associated with tegaserod and was generally mild and transient.Overall, tegaserod has been demonstrated to offer effective and well-tolerated treatment of IBS-C, providing patients with meaningful symptom relief.

View Article: PubMed Central - PubMed

ABSTRACT
Irritable bowel syndrome with constipation (IBS-C) as the predominant bowel symptom is a prevalent disorder, characterized by recurring abdominal pain/discomfort, bloating, and constipation, and imposes a significant socio-economic burden. Traditional treatments generally address just one of the multiple IBS symptoms. The efficacy and safety profile of tegaserod, a serotonin 5-HT(4) receptor agonist, has been demonstrated in several randomized, placebo-controlled, and open-label trials. This review discusses the major clinical trials of tegaserod, which have involved 8948 IBS patients. Overall, data reveal that tegaserod is an effective treatment for IBS-C, providing statistically significant relief of overall and multiple individual IBS-C symptoms (abdominal pain/discomfort, bloating, and constipation) in both placebo-controlled and "real-life" open-label settings. Repeat treatments with tegaserod were also shown to be effective, which is noteworthy given the chronic and episodic nature of IBS. Moreover, tegaserod was associated with improvements in patients' quality of life and work productivity. Data also indicate that tegaserod is well tolerated over the short-term (4 weeks), long-term (12 months), and repeated treatments. Diarrhea is the only adverse event consistently associated with tegaserod and was generally mild and transient. Overall, tegaserod has been demonstrated to offer effective and well-tolerated treatment of IBS-C, providing patients with meaningful symptom relief.

No MeSH data available.


Related in: MedlinePlus

Subject’s Global Assessment (SGA) of Relief demonstrates consistent improvement across tegaserod clinical trials.Note: ***p<0.001.Abbreviations: P1, first treatment cycle; P2, second treatment cycle.
© Copyright Policy
Related In: Results  -  Collection


getmorefigures.php?uid=PMC1936292&req=5

fig1: Subject’s Global Assessment (SGA) of Relief demonstrates consistent improvement across tegaserod clinical trials.Note: ***p<0.001.Abbreviations: P1, first treatment cycle; P2, second treatment cycle.

Mentions: In Studies 1–3, tegaserod provided significantly greater relief of overall IBS symptoms during nearly all weeks of treatment compared with placebo (p<0.05, Figure 1) (Lefkowitz et al 1999; Müller-Lissner et al 2001; Novick et al 2002). Tegaserod also significantly improved individual IBS symptoms, including abdominal pain/discomfort, bloating, and constipation (increased stool frequency and softened stools) compared with placebo (Lefkowitz et al 1999; Müller-Lissner et al 2001; Novick et al 2002). After withdrawal of treatment, IBS symptoms returned rapidly, but did not reach baseline levels (Novick et al 2002).


Tegaserod in the treatment of irritable bowel syndrome (IBS) with constipation as the prime symptom.

Layer P, Keller J, Loeffler H, Kreiss A - Ther Clin Risk Manag (2007)

Subject’s Global Assessment (SGA) of Relief demonstrates consistent improvement across tegaserod clinical trials.Note: ***p<0.001.Abbreviations: P1, first treatment cycle; P2, second treatment cycle.
© Copyright Policy
Related In: Results  -  Collection

Show All Figures
getmorefigures.php?uid=PMC1936292&req=5

fig1: Subject’s Global Assessment (SGA) of Relief demonstrates consistent improvement across tegaserod clinical trials.Note: ***p<0.001.Abbreviations: P1, first treatment cycle; P2, second treatment cycle.
Mentions: In Studies 1–3, tegaserod provided significantly greater relief of overall IBS symptoms during nearly all weeks of treatment compared with placebo (p<0.05, Figure 1) (Lefkowitz et al 1999; Müller-Lissner et al 2001; Novick et al 2002). Tegaserod also significantly improved individual IBS symptoms, including abdominal pain/discomfort, bloating, and constipation (increased stool frequency and softened stools) compared with placebo (Lefkowitz et al 1999; Müller-Lissner et al 2001; Novick et al 2002). After withdrawal of treatment, IBS symptoms returned rapidly, but did not reach baseline levels (Novick et al 2002).

Bottom Line: Moreover, tegaserod was associated with improvements in patients' quality of life and work productivity.Diarrhea is the only adverse event consistently associated with tegaserod and was generally mild and transient.Overall, tegaserod has been demonstrated to offer effective and well-tolerated treatment of IBS-C, providing patients with meaningful symptom relief.

View Article: PubMed Central - PubMed

ABSTRACT
Irritable bowel syndrome with constipation (IBS-C) as the predominant bowel symptom is a prevalent disorder, characterized by recurring abdominal pain/discomfort, bloating, and constipation, and imposes a significant socio-economic burden. Traditional treatments generally address just one of the multiple IBS symptoms. The efficacy and safety profile of tegaserod, a serotonin 5-HT(4) receptor agonist, has been demonstrated in several randomized, placebo-controlled, and open-label trials. This review discusses the major clinical trials of tegaserod, which have involved 8948 IBS patients. Overall, data reveal that tegaserod is an effective treatment for IBS-C, providing statistically significant relief of overall and multiple individual IBS-C symptoms (abdominal pain/discomfort, bloating, and constipation) in both placebo-controlled and "real-life" open-label settings. Repeat treatments with tegaserod were also shown to be effective, which is noteworthy given the chronic and episodic nature of IBS. Moreover, tegaserod was associated with improvements in patients' quality of life and work productivity. Data also indicate that tegaserod is well tolerated over the short-term (4 weeks), long-term (12 months), and repeated treatments. Diarrhea is the only adverse event consistently associated with tegaserod and was generally mild and transient. Overall, tegaserod has been demonstrated to offer effective and well-tolerated treatment of IBS-C, providing patients with meaningful symptom relief.

No MeSH data available.


Related in: MedlinePlus